A Phase 3 interventional study of Valsartan in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 36 sites in 10 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2021-09-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 110th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 81st registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 6 Months to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 179th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 120th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and tolerability of long-term use (up to 18 weeks) of valsartan in children 6 months to 5 years old with hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.
Drug: Valsartan
Extemporaneous suspension of valsartan, orally.
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sitting systolic blood pressure (SSBP) measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.
Time frame: Baseline to Week 26
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three SDBP measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.
Time frame: Baseline to Week 26
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.
Time frame: Week 8 to Week 26 of Extension Phase
The study was conducted at 35 investigative sites in 10 countries from 9 April 2007 to 25 March 2009.
| Milestone | Valsartan Open Label |
|---|---|
| Started | 66 |
| Completed | 60 |
| Not completed | 6 |
| Withdrew: Adverse event | 3 |
| Withdrew: Administrative problems | 2 |
| Withdrew: Participant's condition no longer requires study drug | 1 |
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sitting systolic blood pressure (SSBP) measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.
| millimeters of mercury (mmHg) | Valsartan Open Label |
|---|---|
| Baseline | 114.7 ± 9.04 |
| Change from Baseline at Week 26 | -11.2 ± 12.56 |
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three SDBP measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.
| mmHg | Valsartan Open Label |
|---|---|
| Baseline | 70.7 ± 11.14 |
| Change from Baseline at Week 26 | -6.6 ± 11.84 |
An AE was defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.
| Participants | Valsartan Open Label |
|---|---|
| AEs | 38 |
| SAEs | 4 |
Collected over Week 8 to Week 26 of Extension Phase. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan Open Label | 0/66 (0%) | 4/66 (6.1%) | 38/66 (57.6%) |
| Event | Valsartan Open Label |
|---|---|
| Viral infectionInfections and infestations | 1/66 |
| ContusionInjury, poisoning and procedural complications | 1/66 |
| Head injuryInjury, poisoning and procedural complications | 1/66 |
| WoundInjury, poisoning and procedural complications | 1/66 |
| Nephrotic syndromeRenal and urinary disorders | 1/66 |
| Event | Valsartan Open Label |
|---|---|
| PyrexiaGeneral disorders | 11/66 |
| NasopharyngitisInfections and infestations | 7/66 |
| BronchitisInfections and infestations | 5/66 |
| Upper respiratory tract infectionInfections and infestations | 5/66 |
| Viral infectionInfections and infestations | 4/66 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/66 |
| DiarrhoeaGastrointestinal disorders | 3/66 |
| VomitingGastrointestinal disorders | 3/66 |
| Ear infectionInfections and infestations | 3/66 |
| PharyngitisInfections and infestations | 3/66 |
Enrolled extension participants (ENRE) included all participants who were enrolled into this extension study.
| Age, Continuous(years) | Valsartan Open Label |
|---|---|
| Mean | 3.4 ± 1.41 |
| Sex: Female, Male(Participants) | Valsartan Open Label |
|---|---|
| Female | 23 |
| Male | 43 |
Ran from Apr 2007 to primary completion in May 2009, 25 months.
Results were first posted in May 2021, 11 years 11 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 25 months is above that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valsartan